Chugai ups forecast on strong Tamiflu and oncology sales
This article was originally published in Scrip
Executive Summary
Roche's Japanese subsidiary Chugai has raised its consolidated net profit forecast for the current fiscal year by ¥6.0 billion to ¥46.0 billion ($521.0 million), on the back of stronger than expected sales of Tamiflu and oncology products.